Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.16 which represents a decrease of $-0.10 or -7.94% from the prior close of $1.26. The stock opened at $1.24 and touched a low of $1 ...

It has been about a month since the last earnings report for Editas Medicine (EDIT). Shares have lost about 36.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.31 which represents a slight increase of $0.04 or 3.15% from the prior close of $1.27. The stock opened at $1.27 and touched ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The firm’s revenue was down 98.9% on a year-over-year basis. During the same period in the prior ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...